The features of adipose-derived stem cells in patients with inflammatory bowel diseases

Tsunekazu Mizushima, Tadafumi Fukata, Hiroshi Takeyama, Hidekazu Takahashi, Naotsugu Haraguchi, Junichi Nishimura, Taishi Hata, Chu Matsuda, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

Abstract

Purpose: The treatment outcomes for inflammatory bowel disease (IBD) have been improving, but the development of better therapies is needed. Stem cell therapy is promising, but little is known about the differences in adipose-derived stem cells (ADSCs) between IBD patients and healthy individuals. Methods: ADSCs were isolated from subcutaneous adipose tissue (SAT) in IBD (Crohn’s disease, 3; ulcerative colitis, 2) and non-IBD (colorectal cancer, 5; breast cancer, 1) patients. We also analyzed the effects of tumor necrosis factor (TNF)-α on murine ADSCs. Results: The numbers of stromal vascular fraction (SVF) cells per gram of SAT were 7.72 ± 3.03 × 105 in IBD and 8.51 ± 8.80 × 105 in non-IBD patients (p > 0.05). The proportions of ADSCs in SVF cells were 4.98 ± 2.61% in IBD and 1.02 ± 0.67% in non-IBD patients. The numbers of ADSCs per gram of SAT were 4.16 ± 2.96 × 104 in IBD and 0.88 ± 1.04 × 104 in non-IBD patients. The proportions and numbers of ADSCs were significantly higher in IBD patients than in non-IBD patients. TNF-α significantly facilitated the proliferation and motility of murine ADSCs. Conclusion: These results showed the potential advantage of freshly isolated autologous ADSCs in IBD patients.

Original languageEnglish
Pages (from-to)352-358
Number of pages7
JournalSurgery today
Volume48
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Inflammatory Bowel Diseases
Stem Cells
Subcutaneous Fat
Blood Vessels
Tumor Necrosis Factor-alpha
Breast Neoplasms
Cell- and Tissue-Based Therapy
Ulcerative Colitis
Crohn Disease
Colorectal Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Mizushima, T., Fukata, T., Takeyama, H., Takahashi, H., Haraguchi, N., Nishimura, J., ... Mori, M. (2018). The features of adipose-derived stem cells in patients with inflammatory bowel diseases. Surgery today, 48(3), 352-358. https://doi.org/10.1007/s00595-017-1591-x

The features of adipose-derived stem cells in patients with inflammatory bowel diseases. / Mizushima, Tsunekazu; Fukata, Tadafumi; Takeyama, Hiroshi; Takahashi, Hidekazu; Haraguchi, Naotsugu; Nishimura, Junichi; Hata, Taishi; Matsuda, Chu; Yamamoto, Hirofumi; Doki, Yuichiro; Mori, Masaki.

In: Surgery today, Vol. 48, No. 3, 01.03.2018, p. 352-358.

Research output: Contribution to journalArticle

Mizushima, T, Fukata, T, Takeyama, H, Takahashi, H, Haraguchi, N, Nishimura, J, Hata, T, Matsuda, C, Yamamoto, H, Doki, Y & Mori, M 2018, 'The features of adipose-derived stem cells in patients with inflammatory bowel diseases', Surgery today, vol. 48, no. 3, pp. 352-358. https://doi.org/10.1007/s00595-017-1591-x
Mizushima T, Fukata T, Takeyama H, Takahashi H, Haraguchi N, Nishimura J et al. The features of adipose-derived stem cells in patients with inflammatory bowel diseases. Surgery today. 2018 Mar 1;48(3):352-358. https://doi.org/10.1007/s00595-017-1591-x
Mizushima, Tsunekazu ; Fukata, Tadafumi ; Takeyama, Hiroshi ; Takahashi, Hidekazu ; Haraguchi, Naotsugu ; Nishimura, Junichi ; Hata, Taishi ; Matsuda, Chu ; Yamamoto, Hirofumi ; Doki, Yuichiro ; Mori, Masaki. / The features of adipose-derived stem cells in patients with inflammatory bowel diseases. In: Surgery today. 2018 ; Vol. 48, No. 3. pp. 352-358.
@article{9ebbe82218394adf8e7951833ea34f93,
title = "The features of adipose-derived stem cells in patients with inflammatory bowel diseases",
abstract = "Purpose: The treatment outcomes for inflammatory bowel disease (IBD) have been improving, but the development of better therapies is needed. Stem cell therapy is promising, but little is known about the differences in adipose-derived stem cells (ADSCs) between IBD patients and healthy individuals. Methods: ADSCs were isolated from subcutaneous adipose tissue (SAT) in IBD (Crohn’s disease, 3; ulcerative colitis, 2) and non-IBD (colorectal cancer, 5; breast cancer, 1) patients. We also analyzed the effects of tumor necrosis factor (TNF)-α on murine ADSCs. Results: The numbers of stromal vascular fraction (SVF) cells per gram of SAT were 7.72 ± 3.03 × 105 in IBD and 8.51 ± 8.80 × 105 in non-IBD patients (p > 0.05). The proportions of ADSCs in SVF cells were 4.98 ± 2.61{\%} in IBD and 1.02 ± 0.67{\%} in non-IBD patients. The numbers of ADSCs per gram of SAT were 4.16 ± 2.96 × 104 in IBD and 0.88 ± 1.04 × 104 in non-IBD patients. The proportions and numbers of ADSCs were significantly higher in IBD patients than in non-IBD patients. TNF-α significantly facilitated the proliferation and motility of murine ADSCs. Conclusion: These results showed the potential advantage of freshly isolated autologous ADSCs in IBD patients.",
author = "Tsunekazu Mizushima and Tadafumi Fukata and Hiroshi Takeyama and Hidekazu Takahashi and Naotsugu Haraguchi and Junichi Nishimura and Taishi Hata and Chu Matsuda and Hirofumi Yamamoto and Yuichiro Doki and Masaki Mori",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s00595-017-1591-x",
language = "English",
volume = "48",
pages = "352--358",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - The features of adipose-derived stem cells in patients with inflammatory bowel diseases

AU - Mizushima, Tsunekazu

AU - Fukata, Tadafumi

AU - Takeyama, Hiroshi

AU - Takahashi, Hidekazu

AU - Haraguchi, Naotsugu

AU - Nishimura, Junichi

AU - Hata, Taishi

AU - Matsuda, Chu

AU - Yamamoto, Hirofumi

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Purpose: The treatment outcomes for inflammatory bowel disease (IBD) have been improving, but the development of better therapies is needed. Stem cell therapy is promising, but little is known about the differences in adipose-derived stem cells (ADSCs) between IBD patients and healthy individuals. Methods: ADSCs were isolated from subcutaneous adipose tissue (SAT) in IBD (Crohn’s disease, 3; ulcerative colitis, 2) and non-IBD (colorectal cancer, 5; breast cancer, 1) patients. We also analyzed the effects of tumor necrosis factor (TNF)-α on murine ADSCs. Results: The numbers of stromal vascular fraction (SVF) cells per gram of SAT were 7.72 ± 3.03 × 105 in IBD and 8.51 ± 8.80 × 105 in non-IBD patients (p > 0.05). The proportions of ADSCs in SVF cells were 4.98 ± 2.61% in IBD and 1.02 ± 0.67% in non-IBD patients. The numbers of ADSCs per gram of SAT were 4.16 ± 2.96 × 104 in IBD and 0.88 ± 1.04 × 104 in non-IBD patients. The proportions and numbers of ADSCs were significantly higher in IBD patients than in non-IBD patients. TNF-α significantly facilitated the proliferation and motility of murine ADSCs. Conclusion: These results showed the potential advantage of freshly isolated autologous ADSCs in IBD patients.

AB - Purpose: The treatment outcomes for inflammatory bowel disease (IBD) have been improving, but the development of better therapies is needed. Stem cell therapy is promising, but little is known about the differences in adipose-derived stem cells (ADSCs) between IBD patients and healthy individuals. Methods: ADSCs were isolated from subcutaneous adipose tissue (SAT) in IBD (Crohn’s disease, 3; ulcerative colitis, 2) and non-IBD (colorectal cancer, 5; breast cancer, 1) patients. We also analyzed the effects of tumor necrosis factor (TNF)-α on murine ADSCs. Results: The numbers of stromal vascular fraction (SVF) cells per gram of SAT were 7.72 ± 3.03 × 105 in IBD and 8.51 ± 8.80 × 105 in non-IBD patients (p > 0.05). The proportions of ADSCs in SVF cells were 4.98 ± 2.61% in IBD and 1.02 ± 0.67% in non-IBD patients. The numbers of ADSCs per gram of SAT were 4.16 ± 2.96 × 104 in IBD and 0.88 ± 1.04 × 104 in non-IBD patients. The proportions and numbers of ADSCs were significantly higher in IBD patients than in non-IBD patients. TNF-α significantly facilitated the proliferation and motility of murine ADSCs. Conclusion: These results showed the potential advantage of freshly isolated autologous ADSCs in IBD patients.

UR - http://www.scopus.com/inward/record.url?scp=85031414181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031414181&partnerID=8YFLogxK

U2 - 10.1007/s00595-017-1591-x

DO - 10.1007/s00595-017-1591-x

M3 - Article

VL - 48

SP - 352

EP - 358

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 3

ER -